AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from ...
Nasdaq

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious ...
News Medical

First study to report isolation of M. saskatchewanense from medical devices

In a recent study published in Scientific Reports, researchers reported the first isolation of M. saskatchewanense from medical-grade equipment. Molecular tests based on deoxyribonucleic acid (DNA) ...
Nature

Population-Level Frequency of Fluoroquinolone Resistance by Whole-Genome Sequencing Drug Predictions in Mycobacterium tuberculosis Complex Isolates in England From 2017 Through ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...